Cargando…
Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
BACKGROUND: Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact of cost nor how to integrate cost into medic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238635/ https://www.ncbi.nlm.nih.gov/pubmed/35723002 http://dx.doi.org/10.1161/JAHA.121.023789 |